REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Visgeneer Inc. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Visgeneer Inc. Profile Updated: July 05, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

VISGENEER is a biotech company located in Hsinchu, Taiwan, and is granted as an "Enterprises in the Newly Emerging, Important and Strategic Industries (#09500828690) " by the ministry of Economic Affairs. Visgeneer aims to develop and produce biomedical products associated with human diseases (cancer, cardiovascular disease, diabetes and gout etc.) and skin aging.

Headquarters
No.335, Sec. 6, Zhonghua Rd
Hsinchu City; Hsinchu City;

Contact Details: Purchase the Visgeneer Inc. report to view the information.

Website: http://www.visgeneer.com.tw

Basic Information
Total Employees:
Purchase the Visgeneer Inc. report to view the information.
Outstanding Shares:
Purchase the Visgeneer Inc. report to view the information.
Financial Auditors:
Purchase the Visgeneer Inc. report to view the information.
Incorporation Date:
November 15, 2005
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
10.43%
Purchase this report to view the information.
6.68%
Purchase this report to view the information.
1.94%
Purchase this report to view the information.
0.34%
Purchase this report to view the information.
Subsidiaries
暐正生物科技股份有限公司
100%
Company Performance
Financial values in the chart are available after Visgeneer Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
-38.46%▼
Total operating revenue
-38.46%▼
Operating profit (EBIT)
-217.2%▼
EBITDA
N/A
Net Profit (Loss) for the Period
-406.41%▼
Total assets
-10.91%▼
Total equity
-13.58%▼
Operating Profit Margin (ROS)
-22.12%▼
Net Profit Margin
-27.2%▼
Return on Equity (ROE)
-5.98%▼
Debt to Equity Ratio
11.42%▲
Quick Ratio
-2.81%▼
Cash Ratio
-1.8%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo